Skip to content

The Lots of News and State Taxes, Too Edition | Essential: The Pharmacy Compounding Podcast

Pharmacy Podcast Network

33m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

This episode covers compounding pharmacy news and deep-dives into the complex, often overlooked world of multi-state tax obligations for compounding pharmacies. Andrew Cantor leads the news segment discussing peptides, FDA enforcement actions, animal drug compounding guidances, and credit card processing savings for members. Then, Sarah Dirk interviews CPA Scott Sykes to unpack state sales tax nexus, income tax obligations, gross receipt taxes, and pet medication rules for pharmacies shipping across state lines. The discussion highlights why multi-state shipping creates hidden audit risks and valuation hurdles during a future sale.

  • Multi-state compounding operations must actively track transaction counts, prescription volumes, and dollar thresholds for every state they ship into. 12:14
  • Pharmacies shipping across state lines must distinguish between sales tax nexus rules and income tax filing requirements, as they operate independently. 13:12
  • Pet and veterinary medications shipped multi-state introduce complex, granular tax rules that vary significantly by state and county. 22:57
  • Pharmacy owners should retain financial and tax records for at least seven years, or explore voluntary disclosure programs if they failed to file. 23:46

Chapters

  1. 0:05
    Podcast Intro and Compounding News

    The hosts introduce the episode, preview news about peptides and FDA actions, and set the stage for the main discussion on pharmacy taxes.

  2. 0:53
    Peptide Market and Regulatory Response

    Andrew Cantor outlines the unregulated peptide market, the risks to patients, and APC’s proposed regulatory framework to curb the gray market.

  3. 2:50
    Animal-Derived Thyroid Products Petition

    APC discusses the FDA’s reclassification of ADT as biologics, the citizen petition to reverse it, and the broader pushback against the policy.

  4. 4:07
    GLP‑1 Compounding Enforcement Lesson

    The episode explains an FDA enforcement action against a 503A pharmacy for insufficient documentation, emphasizing the need for proper prescriber documentation.

  5. 5:15
    Credit Card Processing Savings for APC Members

    APC members are encouraged to use APC Payments to potentially save significant annual costs on credit card processing.

  6. 6:09
    Parenteral Nutrition Shortage and FDA Guidance

    The FDA’s temporary flexibility for 503A and 503B compounding amid a newborn parenteral nutrition shortage is discussed, noting ingredient supply challenges.

  7. 6:52
    Veterinary Compounding Guidance Proposal

    APC highlights the draft GFI 256B guidance that would extend enforcement discretion to 503B veterinary compounding facilities.

  8. 7:38
    NABP Model Pharmacy Acts Update

    The National Association of Boards of Pharmacy’s updated Model Pharmacy Acts and Rules are reviewed, noting APC’s influence on key recommendations.

  9. 8:36
    Deep Dive: State Tax Issues for Compounding Pharmacies

    The hosts introduce the main segment, explaining why state taxes are critical for compounding pharmacies and previewing the upcoming interview with CPA Scott Sykes.

  10. 10:06
    Interview Begins: State Sales and Income Tax Nexus

    Scott Sykes explains the complexities of sales tax, income tax, and gross receipt tax nexus for multi‑state compounding pharmacies.

  11. 17:42
    Audit Risks and Proactive Compliance

    Sykes discusses increasing audit activity, the importance of timely filing, and strategies for staying compliant and preparing for potential sales.

  12. 24:52
    Tax Treatment of Compounded Medications and Ingredients

    The conversation turns to how different states tax compounded drugs versus their ingredients and the challenges of multi‑state shipping.

Highlights

  • 0:53

    The Unregulated Peptide Gray Marketinsight

    Unapproved peptides pushed heavily by platforms like TikTok are being sold outside the regulated healthcare system, raising serious patient safety concerns and prompting calls for a safe compounding pathway.

  • 4:38

    GLP-1 Enforcement and Documentationdata

    The FDA took enforcement action against a 503A pharmacy dispensing compounded GLP-1s not over volume, but due to a lack of documentation showing how prescribers determined significant clinical difference.

  • 11:27

    Multi-State Shipping Tax Surprisesinsight

    Compounding pharmacies frequently assume that shipping prescriptions out of state is simple, but operating across state lines opens up a complicated can of worms regarding sales and income tax nexus.

  • 22:24

    The Complication of Pet Prescriptionsinsight

    Shipping veterinary and pet medications across state lines creates a massive compliance headache because taxability rules differ wildly by state and local county.

  • 23:37

    State Tax Records and Statutesstrategy

    While the normal statute of limitations is three years if a pharmacy has been filing, states can go back indefinitely if required tax returns were never filed.

  • 29:28

    California Franchise Tax Ruledata

    Even a single dollar of sales or minimal activity in California triggers an automatic requirement to file and pay the state's eight-hundred-dollar franchise tax fee.

  • 29:34

    Anticipating Increased State Auditsdata

    As states adopt increasingly sophisticated technology to pinpoint economic activity, tax experts expect an increase in state sales and franchise tax audits over the next decade.

Quotes

  • “Peptides are big news, and they're also, you know, big business.”
    Unnamed speaker · 0:53
  • “Prescriber judgment, it's important, but so is taking the time to document that judgment.”
    Unnamed speaker · 5:04
  • “If you're shipping in multi-state or operating in multi-state, you absolutely need to be aware of the state sales tax nexus issues.”
    Unnamed speaker · 10:39
  • “If you haven't been filing in a state and you're required to, then there's no statute of limitations there because you haven't started it. And so they can go back as far as they want.”
    Unnamed speaker · 23:37

About this episode

Peptides. Animal-derived thyroid products. The perils of not documenting enough. A new recommendation for state regulation. And more. Besides the most interesting (and important) news from the pharmacy compounding world, this episode we’ve got a deep dive into the unique tax issues compounders face — which can be pretty darned daunting. Links from the episodeAPC issue brief on peptide compounding (two-page PDF): https://fllw.me/47mZu7bCitizen petition to FDA on compounding ADT (83-page (!) PDF): https://fllw.me/3VeA9twFDA’s proposed GFI 256B — info and a chance to comment: https://www.regulations.gov/search?searchTerm=FDA-2018-D-4533APC’s exclusive processing rates: https://apcpayments.comNABP’s model pharmacy act: https://nabp.pharmacy/members/board-resources/model-pharmacy-act-rules/Sykes & Company Pharmacy Accounting Services: https://www.sykes-cpa.com/compounding-pharmacy-services

Transcript

0:00
33:19

5,401 words · 4 speakers

Topics

  • APC
  • Public Law 86272
  • 503A
  • NABP
  • 503B
  • GLP-1
  • GFI 256B
  • GFI 256
  • AD

Page updated · transcript and summary are machine-generated